6617 Stock Overview
A clinical-stage biopharmaceutical company, develops anticancer drugs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gongwin Biopharm Holdings Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$181.00 |
| 52 Week High | NT$279.50 |
| 52 Week Low | NT$167.00 |
| Beta | 0.84 |
| 1 Month Change | 0% |
| 3 Month Change | -12.14% |
| 1 Year Change | -35.24% |
| 3 Year Change | -4.49% |
| 5 Year Change | 215.94% |
| Change since IPO | 98.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6617 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -3.7% | 1.8% | 0.6% |
| 1Y | -35.2% | -10.0% | 29.2% |
Return vs Industry: 6617 underperformed the TW Biotechs industry which returned -10% over the past year.
Return vs Market: 6617 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 6617 volatility | |
|---|---|
| 6617 Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6617 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6617's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Yuan Lin Mao | www.gongwinbiopharm.com |
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan.
Gongwin Biopharm Holdings Co., Ltd. Fundamentals Summary
| 6617 fundamental statistics | |
|---|---|
| Market cap | NT$20.51b |
| Earnings (TTM) | -NT$104.90m |
| Revenue (TTM) | NT$24.36m |
842.1x
P/S Ratio-195.6x
P/E RatioIs 6617 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6617 income statement (TTM) | |
|---|---|
| Revenue | NT$24.36m |
| Cost of Revenue | NT$7.85m |
| Gross Profit | NT$16.51m |
| Other Expenses | NT$121.41m |
| Earnings | -NT$104.90m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 67.77% |
| Net Profit Margin | -430.65% |
| Debt/Equity Ratio | 6.3% |
How did 6617 perform over the long term?
See historical performance and comparison